ACORDA TACKLES MULTIPLE SCLEROSIS

ACORDA TACKLES MULTIPLE SCLEROSIS

Acorda Therapeutics isn't your typical biotech. Even before its public debut in early 2006, the company had a commercial product. Zanaflex treats spasticity or muscular spasm, a condition associated with multiple sclerosis. Acorda's newer product is Fampridine-sr, which alleviates walking...

Full description

Saved in:
Bibliographic Details
Published in:Bloomberg businessweek (Online) no. 4029; p. 99
Main Author: By Gene G. Marcial Illustration: Chart: OFF WITH A WHOOSH CHARTS BY ERIC HOFFMANN/BW
Format: Magazine Article
Language:English
Published: New York Bloomberg Finance LP 09-04-2007
Subjects:
Biotechnology industry
Investment policy
Product introduction
Stock prices
United States > US
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acorda Therapeutics isn't your typical biotech. Even before its public debut in early 2006, the company had a commercial product. Zanaflex treats spasticity or muscular spasm, a condition associated with multiple sclerosis. Acorda's newer product is Fampridine-sr, which alleviates walking disabilities caused by MS. Shares of Acorda have been on a tear since Fampridine's first phase III trials yielded strong data.
Bibliography:content type line 24
ObjectType-Feature-1
SourceType-Magazines-1
ISSN:0007-7135
2162-657X